Idarubicin HCl

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 100450

CAS#: 57852-57-0(HCl)

Description: Idarubicin is a semisynthetic 4-demethoxy analogue of the antineoplastic anthracycline antibiotic daunorubicin. Idarubicin intercalates into DNA and interferes with the activity of topoisomerase II, thereby inhibiting DNA replication, RNA transcription and protein synthesis. Due to its high lipophilicity, idarubicin penetrates cell membranes more efficiently than other anthracycline antibiotic compounds.

Chemical Structure

Idarubicin HCl
CAS# 57852-57-0(HCl)

Theoretical Analysis

MedKoo Cat#: 100450
Name: Idarubicin HCl
CAS#: 57852-57-0(HCl)
Chemical Formula: C26H28ClNO9
Exact Mass:
Molecular Weight: 533.958
Elemental Analysis: C, 58.49; H, 5.29; Cl, 6.64; N, 2.62; O, 26.97

Price and Availability

Size Price Availability Quantity
200.0mg USD 2450.0 2 Weeks
500.0mg USD 3250.0 2 Weeks
1.0g USD 4850.0 2 Weeks
2.0g USD 7450.0 2 Weeks
5.0g USD 16950.0 2 Weeks
Bulk inquiry

Related CAS #: 58957-92-9 (free base)   57852-57-0(HCl)  

Synonym: IMI30; IMI-30; IMI 30; NSC256439; NSC-256439; NSC 256439; 4-DMDR; IDA; 4-Demethoxydaunomycin; brand name: Idamycin; IDAMYCIN PFS.

IUPAC/Chemical Name: (7S,9S)-9-acetyl-7-(((2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)-6,9,11-trihydroxy-7,8,9,10-tetrahydrotetracene-5,12-dione hydrochloride


InChi Code: InChI=1S/C26H27NO9.ClH/c1-10-21(29)15(27)7-17(35-10)36-16-9-26(34,11(2)28)8-14-18(16)25(33)20-19(24(14)32)22(30)12-5-3-4-6-13(12)23(20)31;/h3-6,10,15-17,21,29,32-34H,7-9,27H2,1-2H3;1H/t10-,15-,16-,17-,21+,26-;/m0./s1

SMILES Code: O=C1C2=C(O)C([C@@H](O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C[C@](O)(C(C)=O)C4)=C4C(O)=C2C(C5=C1C=CC=C5)=O.[H]Cl

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO, not in water

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Preparing Stock Solutions

The following data is based on the product molecular weight 533.958 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.


Dilution Calculator

Calculate the dilution required to prepare a stock solution.

1: Vigliotti ML, Dell'Olio M, La Sala A, Romano G, Tartarone A, Mele G, Musto C, Carella AM, Di Renzo N. Primary central nervous system lymphoma (PCNSL) in immunocompetent adults: analysis of a retrospective series of patients treated using idarubicin-containing regimen and radiotherapy. Hematol J. 2004;5(5):453-5. Review. PubMed PMID: 15448676.

2: Crivellari D, Lombardi D, Spazzapan S, Veronesi A, Toffoli G. New oral drugs in older patients: a review of idarubicin in elderly patients. Crit Rev Oncol Hematol. 2004 Feb;49(2):153-63. Review. PubMed PMID: 15012975.

3: Leone G, Sica S, Pagano L. Idarubicin including regimens in acute myelogenous leukemia in elderly patients. Crit Rev Oncol Hematol. 1999 Sep;32(1):59-68. Review. PubMed PMID: 10586356.

4: Zinzani PL. Idarubicin in low-grade non-Hodgkin's lymphomas. Haematologica. 1997 Sep-Oct;82(5 Suppl):23-4. Review. PubMed PMID: 9402750.

5: Buckley MM, Lamb HM. Oral idarubicin. A review of its pharmacological properties and clinical efficacy in the treatment of haematological malignancies and advanced breast cancer. Drugs Aging. 1997 Jul;11(1):61-86. Review. PubMed PMID: 9237041.

6: Borchmann P, Hübel K, Schnell R, Engert A. Idarubicin: a brief overview on pharmacology and clinical use. Int J Clin Pharmacol Ther. 1997 Feb;35(2):80-3. Review. PubMed PMID: 9147715.

7: Tamura K. A phase I study of idarubicin hydrochloride in patients with acute leukemia. The Idarubicin Study Group of Japan. Semin Hematol. 1996 Oct;33(4 Suppl 3):2-11. Review. PubMed PMID: 8916310.

8: Leoni F, Ciolli S, Giuliani G, Pascarella A, Caporale R, Salti F, Cervi L, Rossi Ferrini P. Attenuated-dose idarubicin in acute myeloid leukaemia of the elderly: pharmacokinetic study and clinical results. Br J Haematol. 1995 May;90(1):169-74. Review. PubMed PMID: 7786781.

9: Gabel C, Eifel PJ, Tornos C, Burke TW. Radiation recall reaction to idarubicin resulting in vaginal necrosis. Gynecol Oncol. 1995 May;57(2):266-9. Review. PubMed PMID: 7729748.

10: Chalmers EA, Franklin IM, Kelsey S, Clarke R, Sproul AM, Goldstone AH, Hepplestone A, Watson W, Sharp S, Tansey P. Mobilisation of Ph-negative peripheral blood stem cells in CML with idarubicin and cytarabine. Bone Marrow Transplant. 1994;14 Suppl 3:S38-41. Review. PubMed PMID: 7697006.

Additional Information

Related CAS#
CAS#57852-57-0( Idarubicin HCl)
CAS#58957-92-9 ( Idarubicin free base).